S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
Log in
NASDAQ:CODX

Co-Diagnostics Stock Forecast, Price & News

$12.12
-0.49 (-3.89 %)
(As of 10/22/2020 04:48 PM ET)
Add
Compare
Today's Range
$11.90
Now: $12.12▼
$12.66
50-Day Range
$8.24
MA: $13.19▼
$15.17
52-Week Range
$0.85
Now: $12.12▼
$30.99
Volume1.11 million shs
Average Volume7.11 million shs
Market Capitalization$340.37 million
P/E Ratio67.33
Dividend YieldN/A
Beta-3.2
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
Read More
Co-Diagnostics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.43 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CODX
Previous Symbol
CUSIPN/A
CIK1692415
Webwww.codiagnostics.com
Phone801-438-1036
Employees39

Debt

Debt-to-Equity RatioN/A
Current Ratio11.57
Quick Ratio8.18

Price-To-Earnings

Trailing P/E Ratio67.33
Forward P/E Ratio7.48
P/E GrowthN/A

Sales & Book Value

Annual Sales$220,000.00
Price / Sales1,547.12
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.10 per share
Price / Book121.20

Profitability

EPS (Most Recent Fiscal Year)($0.36)
Net Income$-6,200,000.00
Net Margins31.42%
Return on Equity56.17%
Return on Assets51.41%

Miscellaneous

Outstanding Shares28,083,000
Market Cap$340.37 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$12.12
-0.49 (-3.89 %)
(As of 10/22/2020 04:48 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

How has Co-Diagnostics' stock been impacted by COVID-19?

Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CODX shares have decreased by 8.1% and is now trading at $12.12.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Co-Diagnostics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Co-Diagnostics.

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Co-Diagnostics.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) announced its quarterly earnings data on Thursday, August, 13th. The company reported $0.43 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.59 by $0.16. The company had revenue of $24.04 million for the quarter, compared to the consensus estimate of $27 million. Co-Diagnostics had a net margin of 31.42% and a return on equity of 56.17%.
View Co-Diagnostics' earnings history.

What price target have analysts set for CODX?

2 brokers have issued 1 year price objectives for Co-Diagnostics' shares. Their forecasts range from $30.00 to $33.00. On average, they anticipate Co-Diagnostics' stock price to reach $31.50 in the next year. This suggests a possible upside of 159.9% from the stock's current price.
View analysts' price targets for Co-Diagnostics.

Are investors shorting Co-Diagnostics?

Co-Diagnostics saw a decline in short interest in the month of September. As of September 30th, there was short interest totaling 6,920,000 shares, a decline of 17.6% from the September 15th total of 8,400,000 shares. Based on an average daily trading volume, of 3,950,000 shares, the short-interest ratio is currently 1.8 days.
View Co-Diagnostics' Short Interest.

Who are some of Co-Diagnostics' key competitors?

Some companies that are related to Co-Diagnostics include Atrion (ATRI), Cerus (CERS), OraSure Technologies (OSUR), Luminex (LMNX), OrthoPediatrics (KIDS), GenMark Diagnostics (GNMK), Vapotherm (VAPO), Alphatec (ATEC), Acutus Medical (AFIB), MiMedx Group (MDXG), CryoLife (CRY), Tactile Systems Technology (TCMD), Orthofix Medical (OFIX), SI-Bone (SIBN) and LeMaitre Vascular (LMAT).
View all competitors.

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Ibio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the following people:
  • Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 67, Pay $295k)
  • Dr. Brent C. Satterfield, Co-Founder & Chief Science Officer (Age 43, Pay $237.5k)
  • Mr. Reed L. Benson, CFO & Sec. (Age 72, Pay $215k)
  • Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry, Head of Commercialization LATAM/EUR

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional investors include Strategic Wealth Management Group LLC (0.05%). Company insiders that own Co-Diagnostics stock include Eugene Durenard and Richard S Serbin.
View institutional ownership trends for Co-Diagnostics.

Which major investors are selling Co-Diagnostics stock?

CODX stock was sold by a variety of institutional investors in the last quarter, including Strategic Wealth Management Group LLC. Company insiders that have sold Co-Diagnostics company stock in the last year include Eugene Durenard, and Richard S Serbin.
View insider buying and selling activity for Co-Diagnostics.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $12.12.

How big of a company is Co-Diagnostics?

Co-Diagnostics has a market capitalization of $340.37 million and generates $220,000.00 in revenue each year. The company earns $-6,200,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Co-Diagnostics employs 39 workers across the globe.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is www.codiagnostics.com.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company can be reached via phone at 801-438-1036 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.